A study to investigate pharmacokinetics, safety, and tolerability of Cefepime-Enmetazobactam administered by intra-venous infusion over 2 hours in participants aged from birth to less than 18 years hospitalized with cUTI including AP.

Exblifep (cefepime/enmetazobactam) - Allecra

Nov 3, 2022